Systematic review of intravitreal bevacizumab injection for treatment of primary diabetic macular oedema

Acta Ophthalmologica

Volumn 89, Issue 8, 2011, Pages 709-717

  Yilmaz, Taygan ^a   Cordero Coma, Miguel ^b   Gallagher, Michéal J ^c   Teasley, Laura A ^d  

^a STONY BROOK UNIVERSITY   (United States)

^b HOSPITAL DE LEÓN   (Spain)

^c Hermitage Medical Clinic   (Ireland)

^d Inland Valley Retina   (United States)

Author keywords

bevacizumab; diabetes; macular oedema; triamcinolone acteonide

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE ACETONIDE;

ANEMIA; ANTERIOR CHAMBER REACTION; CENTRAL MACULAR THICKNESS; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; FOLLOW UP; HEART INFARCTION; HUMAN; INFECTION; INTRAOCULAR HYPERTENSION; KIDNEY FUNCTION; LASER COAGULATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA DETACHMENT; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOSIS; UVEITIS; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; VITREOUS HEMORRHAGE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 82155197239     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2010.01918.x     Document Type: Review

References (24)

1. Ahmadieh H, Ramezani A, Shoeibi N, et al., (2008): Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular oedema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 246: 483-489. (Pubitemid 351447960)
2. Chun DW, Heier JS, Topping TM, Duker JS, &, Bankert JM, (2006): A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular oedema. Ophthalmology 113: 1706-1712. (Pubitemid 44442451)
3. Deeks J, Higgins J, &, Altman D, Analysing and presenting results. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6. [updated September 2006]; Section 8. In: The Cochrane Library, Issue 4, 2006.
4. Diabetic Retinopathy Clinical Research Network (2007): A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular oedema. Ophthalmology 114: 1860-1867.
5. Diabetic Retinopathy Clinical Research Network (2008): A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular oedema. Ophthalmology 115: 1447-1449, 1449 e1-10.
6. Diabetic Retinopathy Clinical Research Network (2009): Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular oedema. Arch Ophthalmol 127: 245-251.
7. Early Treatment Diabetic Retinopathy Study Research Group (1985): Photocoagulation for diabetic macular oedema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103: 1796-1806.
8. Early Treatment Diabetic Retinopathy Study Research Group (1987): Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular oedema. Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology 94: 761-774.
9. Early Treatment Diabetic Retinopathy Study Research Group (1991): Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 98 (5 Suppl): 766-785.
10. Faghihi H, Roohipoor R, Mohammadi SF, et al., (2008): Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular oedema. Eur J Ophthalmol 18: 941-948.
11. Fung AE, &, Bhisitkul RB, (2008): Safety monitoring with ocular anti-vascular endothelial growth factor therapies. Br J Ophthalmol 92: 1573-1574.
12. Gillies MC, (2006): What we don't know about avastin might hurt us. Arch Ophthalmol 124: 1478-1479. (Pubitemid 44537150)
13. Higgins J, &, Green S, (eds) (2006): Assessment of study quality. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6. [updated September 2006]; Section 6. In: The Cochrane Library, Issue 4.
14. Jadad AR, Moore RA, Carroll D, et al., (1996): Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12. (Pubitemid 26120810)
15. Klein R, Klein BE, Moss SE, &, Cruickshanks KJ, (1995): The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular oedema. Ophthalmology 102: 7-16.
16. Macugen Diabetic Retinopathy Study Group (2005): A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular oedema. Ophthalmology 112: 1747-1757.
17. Nagasawa T, Naito T, Matsushita S, Sato H, Katome T, &, Shiota H, (2009): Efficacy of intravitreal bevacizumab (Avastin) for short-term treatment of diabetic macular oedema. J Med Invest 56: 111-115.
18. Oosthuyse B, Moons L, Storkebaum E, et al., (2001): Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 28: 131-138. (Pubitemid 32538057)
19. Pan-American Collaborative Retina Study Group (2007): Primary intravitreal bevacizumab (Avastin) for diabetic macular oedema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 114: 743-750.
20. Roth DB, King A, Weiss M, &, Klein D, (2009): Systemic adverse events after bevacizumab. Ophthalmology 116: 1226.e1.
21. Simõ R, &, Hernández C, (2008): Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 51: 1574-1580.
22. Soheilian M, Ramezani A, Bijanzadeh B, et al., (2007): Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular oedema. Retina 27: 1187-1195. (Pubitemid 350211523)
23. Soheilian M, Ramezani A, Obudi A, et al., (2009): Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular oedema. Ophthalmology 116: 1142-1150.
24. Yilmaz T, Weaver CD, Gallagher MJ, et al., (2009): Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular oedema: a systematic review. Ophthalmology 116: 902-911; quiz 912-3. Review.